Indiana University, Indianapolis, IN
MS, Organic Chemistry
Purdue University, Indianapolis, IN
BA, Chemistry and German
Smith College, Northampton, MA
Kati Copley-Merriman, MS, MBA, is Vice President of Market Access and Outcomes Strategy at RTI-HS. Ms. Copley-Merriman has more than 35 years of industry experience, including leadership roles in Global Outcomes Research at Eli Lilly, Parke-Davis, and Pfizer. She has experience in all aspects of outcomes research.
In her RTI-HS role, Ms. Copley-Merriman leads a team of outcomes research scientists, medical writers, and reimbursement experts responsible for developing outcomes research strategic plans, literature reviews, disease state summaries, global value dossiers, and reimbursement dossiers. Ms. Copley-Merriman has experience in many therapeutic areas, including oncology, pain and inflammation, dermatology, respiratory, urology, and central nervous system. Ms. Copley-Merriman is an active member of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and was elected to the ISPOR Board from 2010 to 2012. Ms. Copley-Merriman was also appointed to be a member of the Value in Health editorial advisory board from November 2014 to November 2018.